GlassScriptPhysician profile
Breezy N Wilson
NPI 1679785422
$16,078.66
in general payments reported to CMS, 2019-2025
50 companies · $2,471 in 2025
The $2,471 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $2,075 · 2021: $2,452 · 2022: $2,194 · 2023: $2,193 · 2024: $2,386 · 2025: $2,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,050.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,586.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,925.29 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,544.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $974.92 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $973.62 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.91 | 2019-2023 | |
| Lilly USA, LLC | $852.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $600.06 | 2021-2025 | |
| Pfizer INC. | $491.94 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $453.80 | 2021-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $403.80 | 2019-2024 | Seglentis, Livalo, Zoryve |
| Amarin Pharma, INC. | $346.36 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.21 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $310.78 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $299.87 | 2019-2021 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $253.10 | 2019-2024 | Yupelri |
| Amgen INC. | $237.87 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Assertio Therapeutics, INC. | $236.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $176.26 | 2019-2022 | |
| Dexcom, INC. | $173.99 | 2023-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $171.39 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.22 | 2024-2025 | Caplyta |
| Scilex Pharmaceuticals INC. | $149.72 | 2023-2025 | Ztlido |
| Axsome Therapeutics, INC. | $135.57 | 2022-2025 | Auvelity, Symbravo |
| Ardelyx, INC. | $133.90 | 2024-2025 | Ibsrela |
| Halozyme INC | $107.97 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $107.34 | 2019-2022 | |
| Antares Pharma, INC. | $104.43 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Ironwood Pharmaceuticals, INC | $88.80 | 2020-2024 | |
| Abbott Laboratories | $86.38 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $82.33 | 2022 | |
| Allergan, INC. | $76.25 | 2019-2020 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $67.18 | 2022 | |
| Corium, LLC | $61.55 | 2025 | Azstarys |
| Lundbeck LLC | $59.58 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $57.30 | 2022 | Xyosted, Tlando |
| Exact Sciences Corporation | $51.06 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $45.92 | 2023 | Accrufer |
| Boston Scientific Corporation | $36.94 | 2023-2025 | General - Pain Management |
| Radius Health, INC. | $26.74 | 2020 | |
| Corcept Therapeutics | $26.72 | 2025 | Korlym |
| Eisai INC. | $26.28 | 2021 | |
| Neurocrine Biosciences, INC. | $23.95 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.82 | 2024 | Voquezna |
| Aytu Biopharma, INC. | $17.17 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.09 | 2023 | Nuzyra |
| Zyla Life Sciences, INC. | $14.51 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.36 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Breezy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.